Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan 1;107(1):e417-e419.
doi: 10.1210/clinem/dgab686.

Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver

Ranyao Yang  1   2 , Aimin Xu  1   2   3 , Alexei Kharitonenkov  4
Affiliations
Editorial

Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver

Ranyao Yang et al. J Clin Endocrinol Metab. .
No abstract available

Keywords: fibroblast growth factor 21 (FGF21); hypertriglyceridemia; metabolism; nonalcoholic fatty liver diseases (NAFLD); obesity.

PubMed Disclaimer

Comment on

References

    1. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635. - PMC - PubMed
    1. Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654-667. - PubMed
    1. Talukdar S, Kharitonenkov A. FGF19 and FGF21: in NASH we trust. Mol Metab. 2021;46:101152. - PMC - PubMed
    1. Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019;392(10165):2705-2717. - PubMed
    1. 89bio. https://ir.89bio.com/news-releases/news-release-details/89bio-initiates-...

Substances